Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A Computational Approach for Structural and Functional Analyses of Disease-associated Mutations in the HumanCYLDGene

View through CrossRef
AbstractTumor suppressor Cylindromatosis protein (CYLD) regulates NF- κB and JNK signaling pathway by cleaving K63 linked poly-ubiquitin chain from its substrate molecules and thus preventing the progression of tumorigenesis and metastasis of the cancer cells. Mutations in CYLD can cause aberrant structure and abnormal functionality leading to tumor formation. In this study, we utilized several computational tools such as PANTHER, PROVEAN, PREDICT- SNP, POLYPHEN 2, PHD SNP, PON P2, and SIFT to find out deleterious nsSNPs. We also highlighted the damaging impact of those deleterious nsSNPs on the structure and function of the CYLD utilizing Consurf, I-Mutant, SDM, Phyre2, HOPE, Swiss PDB Viewer, and Mutation 3D. We shortlisted 18 high-risk nsSNPs from a total of 446 nsSNPs recorded in the NCBI database. Based on the conservation profile, stability status, and structural impact analysis we finalized 13nsSNPs. Molecular docking analysis and molecular dynamic simulation concluded the study with the findings of two significant nsSNPs (R830K, H827R) which have a remarkable impact on binding affinity, RMSD, RMSF, Radius of gyration, and hydrogen bond formation during CYLD-ubiquitin interaction. The principal component analysis compared native and two mutants R830K, H827R of CYLD that signifies structural and energy profile fluctuations during molecular dynamic (MD) simulation. Finally, the Protein-protein interaction network showed CYLD interacts with 20 proteins involved in several biological pathways that mutations can impair. Considering all these in silico analyses, our study recommended conducting large-scale association studies of nsSNPs of CYLD with cancer as well as designing precise medications against diseases associated with these polymorphisms.
Title: A Computational Approach for Structural and Functional Analyses of Disease-associated Mutations in the HumanCYLDGene
Description:
AbstractTumor suppressor Cylindromatosis protein (CYLD) regulates NF- κB and JNK signaling pathway by cleaving K63 linked poly-ubiquitin chain from its substrate molecules and thus preventing the progression of tumorigenesis and metastasis of the cancer cells.
Mutations in CYLD can cause aberrant structure and abnormal functionality leading to tumor formation.
In this study, we utilized several computational tools such as PANTHER, PROVEAN, PREDICT- SNP, POLYPHEN 2, PHD SNP, PON P2, and SIFT to find out deleterious nsSNPs.
We also highlighted the damaging impact of those deleterious nsSNPs on the structure and function of the CYLD utilizing Consurf, I-Mutant, SDM, Phyre2, HOPE, Swiss PDB Viewer, and Mutation 3D.
We shortlisted 18 high-risk nsSNPs from a total of 446 nsSNPs recorded in the NCBI database.
Based on the conservation profile, stability status, and structural impact analysis we finalized 13nsSNPs.
Molecular docking analysis and molecular dynamic simulation concluded the study with the findings of two significant nsSNPs (R830K, H827R) which have a remarkable impact on binding affinity, RMSD, RMSF, Radius of gyration, and hydrogen bond formation during CYLD-ubiquitin interaction.
The principal component analysis compared native and two mutants R830K, H827R of CYLD that signifies structural and energy profile fluctuations during molecular dynamic (MD) simulation.
Finally, the Protein-protein interaction network showed CYLD interacts with 20 proteins involved in several biological pathways that mutations can impair.
Considering all these in silico analyses, our study recommended conducting large-scale association studies of nsSNPs of CYLD with cancer as well as designing precise medications against diseases associated with these polymorphisms.

Related Results

Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Abstract Recurrent somatic mutations of CUX1 are described in myeloid neoplasms. CUX1 is located at chromosome 7q22.1; -7/del(7q) involving CUX1 locus are common abn...
Form Follows Force: A theoretical framework for Structural Morphology, and Form-Finding research on shell structures
Form Follows Force: A theoretical framework for Structural Morphology, and Form-Finding research on shell structures
The springing up of freeform architecture and structures introduces many challenges to structural engineers. The main challenge is to generate structural forms with high structural...
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Abstract Introduction. Ultra-deep next generation sequencing (NGS) allows sensitive detection of mutations and estimation of their clonal abundance in tumor cell pop...
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Abstract Introduction: Acute leukemia is a group of clonal heterogeneous diseases with high recurrence rate. The monitoring of minimal residual disease (MRD) after t...
Distinct Profile of FLT3 Mutations in Brazil.
Distinct Profile of FLT3 Mutations in Brazil.
Abstract Mutations in the tyrosine kinase receptor FLT3 are the most common molecular abnormality in acute myeloid leukemia (AML) being detected in about 30% of AML ...
Tracking emerging KRAS, BRAF and EGFR mutations through ccfDNA in colorectal cancers treated with EGFR blockade.
Tracking emerging KRAS, BRAF and EGFR mutations through ccfDNA in colorectal cancers treated with EGFR blockade.
547 Background: Epidermal growth factor receptor (EGFR) blockade can achieve considerable tumor shrinkage in patients with metastatic colorectal cancer (CRC). However, most patien...

Back to Top